Stroke care company Imperative Care Inc revealed on Friday the appointment of Daniel Davis as its chief operating officer.
In the senior position in the company, Davis is responsible for the launch and growth of the breakthrough technologies to treat ischemic stroke patients in the US.
Most recently, Davis has served as chief commercial officer and president of North America, Penumbra, where he launched the first FDA-cleared aspiration system for neurovascular mechanical thrombectomy.
The company said Davis brings 19 years of experience in sales, marketing, and business development with both early stage and Fortune 500 medical device, technology and consumer product companies, focused on bringing neurovascular innovations to market.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT